StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report issued on Wednesday morning. The brokerage issued a sell rating on the medical technology company’s stock.
BIOL has been the subject of a number of other reports. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets dropped their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.
View Our Latest Research Report on BIOL
BIOLASE Price Performance
Institutional Investors Weigh In On BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Read More
- Five stocks we like better than BIOLASE
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 11/18 – 11/22
- What is the S&P/TSX Index?
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.